Material matter: US IND cleared for the phase 1/2 trial of LCB02A, a CLDN18.2 antibody-drug conjugate
DART
LigaChem Biosciences Inc.
Filed May 14, 2026 KST · Filing
· receipt 20260514900334
kstock has not written this one up.
The title above is a translation of the Korean form name; the filing itself is on DART, in
Korean.
Read the original on DART ↗Korean. DART is Korea's electronic disclosure system, run by the Financial Supervisory
Service — the filing equivalent of EDGAR.
Korean form name: 투자판단관련주요경영사항(임상시험계획승인신청등결정) (CLDN18.2 항체-약물 접합체 (ADC) LCB02A의 제 1/2상 임상시험의 미국 임상시험계획(IND) 승인)